June 19, 2019

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Lower Health Care Costs Act.

“While we share the goal of reducing prescription drug costs for consumers, we strongly oppose the legislation, S.1895, introduced today, due to provisions that represent unprecedented government interference in private-sector contracts.

Plain and simple, the legislation takes away choices from employers, unions, and others offering coverage who are best positioned to understand the needs of their enrollees and the optimal design of their prescription drug benefits. At the same time, the bill does little to address high list prices set solely by drug manufacturers.

We urge the committee to reconsider these provisions and refocus on promoting competition and choice.”